CorMedix is a specialty pharmaceutical company focused on anti-infective products for serious, life-threatening infections in hospital and clinic settings. Its core product is DefenCath (taurolidine and heparin), the only FDA-approved antimicrobial catheter lock solution in the U.S., indicated to reduce catheter-related bloodstream infections in kidney failure patients on chronic hemodialysis via central venous catheter. DefenCath replaces plain heparin locks — the standard of care — with a solution that is both anticoagulant and antimicrobial. DefenCath is sold to outpatient dialysis clinics and hospitals, with large dialysis chains as the primary customers. Reimbursement flows through Medicare, with TDAPA providing add-on payments through mid-2026 and NTAP covering the inpatient setting through late 2026. In August 2025, CorMedix acquired Melinta Therapeutics, adding a portfolio of hospital anti-infectives, primarily REZZAYO (rezafungin), a once-weekly IV antifungal for candidemia; MINOCIN IV, an IV antibiotic for resistant gram-negative infections; and VABOMERE, an IV carbapenem combination for carbapenem-resistant bacteria. The Melinta products are sold into hospitals through infectious disease physicians, pharmacists, and formulary committees. CorMedix does not manufacture its own products, relying on third-party contract manufacturers. Key growth priorities include expanding DefenCath adoption among Medicare Advantage plans, a Phase 3 trial of DefenCath in patients receiving total parenteral nutrition, and a Phase 3 trial of REZZAYO as a prophylactic antifungal in bone marrow transplant patients, where top-line data are expected in Q2 2026.